对比剂肾病的研究进展  

Status and progress of contrast media-induced nephropathy

作　　者：熊丹[1] 翟红霞[1] 李良[1] 李娜[1] 王磊[1] 张津津[1] 夏云峰[1] 

机构地区：[1]解放军总医院第一附属医院干一科,北京100048

出　　处：《心脏杂志》2016年第1期110-113,共4页Chinese Heart Journal

摘　　要：自1924年美国用50%的碘化钠成功地做了第一例股动脉造影以来,与介入放射学的发展一样造影剂产品不断的更新换代。发展类别从离子型、非离子型至高渗、等渗及低渗,应用范围从普通的增强CT发展到冠状动脉造影术及冠状动脉介入治疗等,对比剂的应用已不局限于诊断领域,正在逐步向治疗领域发展。使用对比剂在帮助诊断治疗疾病的同时,其副作用也影响着患者的预后,增加医疗费用。目前,对比剂肾病(CIN)已成为医源性肾损害的第3大主要因素,仅次于肾缺血损伤和肾毒性药物所致的肾病。尤其是对于存在慢性肾功能不全(CRI)、糖尿病(DM)等高危因素的人群,CIN的发生率更是明显增加。为此,了解CIN的发生机制,寻找有效的预防措施,减少CIN的发生已是当务之急。本文旨在论述CIN的研究进展,为临床工作者提供参考依据。Since the first successful case of femoral artery angiography using 50% sodium iodide in the United States in 1924, contrast agents have been constantly upgraded from ionic and nonionic contrast media to high, isotonic and hypotonic permeability media. Their applications range from enhanced CT to coronary angiography and coronary artery intervention therapy. Contrast agents are not limited to the field of diagnosis and are gradually applied to treatment. Along with their efficacy in diagnosis and treatment of diseases, side effects of contrast agent products can affect the prognosis and increase medical expenses. Contrast-induced nephropathy （CIN） has become the third major factor for iatrogenic renal damage, only after renal ischemia injury and drug-induced toxicity. The occurrence rate of CIN is obviously increased, especially in patients with chronic renal insufficiency, diabetes mellitus and other risk factors. This paper will discuss the clinical status and progress of contrast-induced nephropathy from the aspects of the occurrence mechanism of CIN and effective preventive measures of CIN so as to provide some reference for clinicians.

关 键 词：对比剂肾病 发病机制 危险因素 预防措施 

分 类 号：R692[医药卫生—泌尿科学]